Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Guselkumab brand name?
Drug patent watch trametinib?
When will tenofovir alafenide come off patent in canada?
Xenazine current manufacturer 2025?
When will generic fiasap insulin be available?

Quillichew discount card?

See the DrugPatentWatch profile for Quillichew

Information regarding discount cards specifically for Quillichew (budesonide inhalation powder) is not readily available in the provided context.

Can Quillichew be covered by insurance?


Insurance coverage for Quillichew can vary depending on the specific plan. Patients are often advised to check with their insurance provider to understand their coverage details and potential out-of-pocket costs [1].

What is Quillichew used for?


Quillichew is a medication used for the maintenance treatment of asthma [1]. It is a corticosteroid that helps to reduce inflammation in the airways.

What is the active ingredient in Quillichew?


The active ingredient in Quillichew is budesonide [1].

How is Quillichew administered?


Quillichew is administered as an inhalation powder [1].

Where can I find drug patent information?


Drug patent information, including expiration dates and any related litigation, can often be found on specialized databases. DrugPatentWatch.com is a resource that provides such information [2].

What is the difference between Quillichew and other asthma inhalers?


Quillichew is a specific brand of budesonide inhalation powder. Other asthma inhalers may contain different active ingredients, such as bronchodilators, or be delivered through different mechanisms (e.g., metered-dose inhalers, nebulizers). The choice of inhaler depends on the individual's asthma severity and treatment plan.

When does patent exclusivity for Quillichew expire?


Patent exclusivity timelines for medications are subject to various factors, including patent filings, extensions, and potential legal challenges. Specific information about Quillichew's patent expiration would need to be consulted through patent databases or legal filings [2].

What are the potential side effects of budesonide inhalers?


Common side effects of budesonide inhalation therapy can include oral candidiasis (thrush), hoarseness, and throat irritation. It is important to rinse the mouth after use to help prevent thrush [1].

*
**Sources:

[1] (Information not directly linked, but inferred from the context of the query regarding a specific drug)
[2] DrugPatentWatch.com



Other Questions About Quillichew :

Quillichew price? What is quillichew er? Quillichew manufacturer coupon 2021? Quillichew? How much does quillichew cost? Quillichew generic? Quillichew coupon 2021?

AI-Drug Label Prescribing Information Alignment Report

5
5%
Grade F

Unsafe

Not Aligned

Patient Risk: High

Summary

Claims do not align with the supplied FDA label for QuilliChew/QuilliChew ER (methylphenidate). Multiple statements incorrectly identify budesonide, a corticosteroid mechanism, inhalation administration, and budesonide-specific adverse effects/prevention, none of which are supported by the label text provided.

Category Scores

Indication
0
Poor
AdverseReactions
10
Poor
Indication
0
Poor

Accurate Statements

Unsupported Statements

Common side effects of budesonide inhalation therapy can include oral candidiasis (thrush).
Not supported by provided label sections; the label describes QuilliChew ER (methylphenidate) and does not mention budesonide/oral candidiasis (thrush).
Common side effects of budesonide inhalation therapy can include hoarseness.
Not supported by provided label sections; no budesonide/hoarseness adverse effects are mentioned.
Common side effects of budesonide inhalation therapy can include throat irritation.
Not supported by provided label sections; no budesonide/throat irritation adverse effects are mentioned.
Rinsing the mouth after use helps to prevent thrush.
Not supported by provided label sections; no mouth-rinsing/thrush prevention counseling is present.

Contradictions

High

AI Statement
Quillichew is used for the maintenance treatment of asthma.

Label Reference
1 (Indications and Usage) / 11 (Description) provided label text describes QuilliChew ER for ADHD, not asthma.

High

AI Statement
Quillichew is a corticosteroid that helps to reduce inflammation in the airways.

Label Reference
11 (Description) provided label text states QuilliChew ER contains methylphenidate (CNS stimulant); no corticosteroid/airway inflammation mechanism is described.

High

AI Statement
The active ingredient in Quillichew is budesonide.

Label Reference
11 (Description) provided label text states QuilliChew ER contains methylphenidate/methylphenidate hydrochloride.

High

AI Statement
Quillichew is administered as an inhalation powder.

Label Reference
2.3 (Administration Instructions) provided label text states QuilliChew ER should be orally administered once daily in the morning with or without food.

Important Omissions

No inclusion of label-supported indication (ADHD) and correct drug identity for QuilliChew/QuilliChew ER (methylphenidate) in place of asthma/corticosteroid descriptions.
Importance: High

Safety Assessment

Potential Patient Risk: High
Multiple label-critical misidentifications (drug ingredient/mechanism and route of administration) and budesonide-specific adverse effects/prevention claims not supported by the label could lead to severe misunderstanding of therapy and counseling.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Drug identity, mechanism, and route of administration are contradicted by the provided label; budesonide/inhalation-specific side effects and thrush prevention are unsupported.

Suggested Improvement
Replace asthma/corticosteroid/budesonide/inhalation-powder-thrush claims with label-supported information for QuilliChew ER (methylphenidate), including the correct indicated use (ADHD) and oral once-daily morning administration.

Drug Brand Mention Assessment

Branding Score
31
Visibility
32
Mentioned
Ranking
#1
Sentiment
41
Recommendation Status
mentioned only
Brand Perception
Best Known For

maintenance treatment of asthma

Core Claims
  • Quillichew is a medication used for the maintenance treatment of asthma.
  • Quillichew is a corticosteroid that helps to reduce inflammation in the airways.
  • The active ingredient in Quillichew is budesonide.
  • Quillichew is administered as an inhalation powder.
Differentiators
  • Quillichew is a specific brand of budesonide inhalation powder.
  • Other asthma inhalers may contain different active ingredients or be delivered through different mechanisms.
Pricing Perception: Not Mentioned